Management of Helicobacter Pylori – An Update

​18 August 2022

Chronic Helicobacter Pylori (H. Pylori) infection has been linked to the development of peptic ulcer disease, MALT lymphoma and Gastric cancer.  H. pylori resistance rates to antibiotics are increasing in most parts of the world with the efficacy of traditional triple therapy in the form of Amoxicillin, Clarithryomycin and proton pump inhibitors dipping to <80% in some regions. The success of eradication of H. pylori rests on the twin arms of antibiotic susceptibility and acid suppression. In this update, we review new treatment paradigms and discuss the role of Vonoprazan (Potassium-Competitive Acid Blocker) in the management of H. pylori.

After the lecture, the participants will be able to gain an understanding on:

• The different antimicrobial treatment regimens for H. pylori
• Factors predicting successful eradication of H. pylori
• Local H. pylori resistance epidemiological data in Singapore
• Potassium Competitive Acid Blockers and their role in the treatment of H. pylori

Click here for more lecture details.

Registration closes on 27 July 2022, Wednesday.

Upon registration, participants agreed to PGAHI Terms & Conditions.  Kindly note that PGAHI reserves the right of final decision on lecture registration.

Lecture Details

Date:

2022, Thursday

Timing:

6.30 pm - 7.30 pm

Duration:

60 minutes

Fees:

Complimentary

Platform:

Zoom Cloud Meetings

Registration Closing Date:

27 July 2022, Wednesday

Target Audience:

Pharmacists 

(Zoom Capacity: 500

This lecture will be conducted via Zoom Cloud Meetings app. For ease of accessing the lecture, please download/update Zoom Cloud Meetings app. Details of the lecture meeting link will be sent to the successful registrants nearer the lecture date.)